Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1999-05-01

AUTHORS

Michael J. McCluskie, Cynthia L. Brazolot Millan, Robert A. Gramzinski, Harriet L. Robinson, Joseph C. Santoro, James T. Fuller, Georg Widera, Joel R. Haynes, Robert H. Purcell, Heather L. Davis

ABSTRACT

BackgroundIn spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.Materials and MethodsEight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six non-injected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.ResultsIn one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 µg) was compared to ID and IM (100 µg) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 µg at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 µg by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.ConclusionsRoute of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required. More... »

PAGES

287-300

Journal

TITLE

Molecular Medicine

ISSUE

5

VOLUME

5

Related Patents

  • Suppression Of Malignancy Utilizing Ribonucleotide Reductase R1
  • Pharmaceutically Purified Intact Bacterial Minicells
  • Superior Molecular Vaccine Linking The Translocation Domain Of A Bacterial Toxin To An Antigen
  • For Treatment Of Atopic Conditions (Dermatitis, Allergies) And Influenza Virus; Point Mutations
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Hiv-1 South African Subtype C Env Proteins
  • Methods Of Using Immunostimulatory Nucleic Acid Molecules To Treat Allergic Conditions
  • Compositions And Methods For Administering Borrelia Dna
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Use Of Immunopotentiating Sequences For Inducing Immune Response
  • Methods For The Early Diagnosis Of Ovarian Cancer
  • Baculovirus Expressing The Exogenous Nucleotide Sequence Porcine Circovirus-B (Pcvb) Open Reading Frame 2; Transformed Host Cells For Expressing Immunogenic Protein For Protecting Pigs Including Pregnant Pigs; Adjuvant
  • Automatic Baroreflex Modulation Responsive To Adverse Event
  • Immunogenic Compositions For Protection Against Chlamydial Infection
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Treating Inflammatory Bowel Disease In Humans; Obtain Human, Administer Drug, Monitor For Reduction In Side Effects From Gastrointestinal Disorder
  • Tuberculosis Therapy; Anticancer Agents
  • Vaccines For Blocking Transmission Of Plasmodium Vivax
  • Treatment Of Immune Disease By Mucosal Delivery Of Antigents Using Genetically Modified Lactobacillus
  • Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Oligodeoxynucleotide And Its Use To Induce An Immune Response
  • Method Of Epitope Discovery
  • Which Contains A Cytosine, Guanine Dinucleotide Sequence And Stimulates (For Example, Has A Mitogenic Effect) Vertebrate Immune Cells
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Measles Vaccine Vectors And Methods Of Use
  • Vaccine Comprising A Polynucleotide Encoding An Antigen Recognized By A Cd4+ Helper T-Cell And A Polynucleotide Encoding A Tumor Specific Or Associated Antigen Recognized By A Cd8+ Ctl
  • Delivery Of Therapeutic Agents By Gene Therapy
  • Induction Of Mucosal Tolerance To Antigens
  • Delivering Dna Encoding Peptide Or Protein Into Cell Of Mammal; Administering Ionizable Transition Metal Compound Enhancer; Gene Expression
  • Methods And Compositions For Treating Prostate Cancer Using Dna Vaccines
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Method To Enhance An Immune Response Of Nucleic Acid Vaccination
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Pharmaceutically Compatible Method For Purifying Intact Bacterial Minicells
  • Molecular Vaccine Linking An Endoplasmic Reticulum Chaperone Polypeptide To An Antigen
  • Administering To A Human, A Naked Dna Comprising A Dna Fragment Encoding A Polypeptide Consisting Essentially Of A Portion Of An Immunogenic Dust Mite Antigen; Fragment Is Amplified By A Primer Pair; Dermatophagoides; Antiallergens
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Dna Vaccine Enhancement With Mhc Class Ii Activators
  • Compositions And Methods For Delivery Of Genetic Material
  • Light Emitting Microorganisms And Cells For Diagnosis And Therapy Of Tumors
  • Immunostimulatory Nucleic Acid Molecules
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Wherein Dna Vaccine Comprises Plasmid Containing Nucleotide Sequence Encoding An Immunogen Of A Pathogen Of Bovine Or Porcine, Under Conditions Allowing The In Vivo Expression Of This Sequence, And A Cationic Lipid Ammonium Salt
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Dna Vaccines And Methods For The Prevention Of Transplantation Rejection
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Forming Densified Nucleic Acid Gene Material Without Biolistic Core Carrier For Transdermal Delivery Needleless Injection
  • Mycobacterial Disease, Malaria, Leishmaniasis, Toxoplasmosis, Schistosomiasis And Clonorchiasis; Antiallergens; Asthma
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Lead Electrode Incorporating Extracellular Matrix
  • Baculovirus Expressing The Exogenous Nucleotide Sequence Porcine Circovirus-B (Pcvb) Open Reading Frame 2; Transformed Host Cells For Expressing Immunogenic Protein For Protecting Pigs Including Pregnant Pigs
  • Aids Virus Vaccines Using Sendai Virus Vector
  • Microorganisms For Therapy
  • Antisense Inhibition Of Rad51
  • Delivery Of Therapeutic Gene Products By Intestinal Cell Expression
  • Epicardial Patch Including Isolated Extracellular Matrix With Pacing Electrodes
  • Light Emitting Microorganisms And Cells For Diagnosis And Therapy Of Diseases Associated With Wounded Or Inflamed Tissue
  • Adjuvant Preparation For The Induction Of Specific Immunity
  • Composition And Method For Inhibiting Tumor Cell Growth
  • Microorganisms For Therapy
  • Use Of Sterically Stabilized Cationic Liposomes To Efficiently Deliver Cpg Oligonucleotides In Vivo
  • Antitumoral Composition Based On Immunogenic Polypeptide With Modified Cell Location
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Induce Immunology Response; Antiallergens; Bioavailability; Autoimmune Disease, Anticancer Agents, Antiallergens
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Expression Of Hiv Polypeptides And Production Of Virus-Like Particles
  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Expression Cassette Generated From These Sequences; Generating An Immune Response In A Subject
  • Use Of Cpg Oligodeoxynucleotides To Induce Epithelial Cell Growth
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Extraneous Dna Sequence That Facilitates Hantavirus Gene Expression
  • Immunostimulatory Nucleic Acid Molecules
  • Recombinant, Thymidylate Synthase Defective, Lactococcus Comprising Heterologous Interleukin-10 Gene For Use As Gene Therapeutic Tool In Treatment Of Inflammatory Bowel Disease
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Methods For Genetic Immunization
  • Induces Production Of A Cytokine Or Activates Dendritic Cells, Natural Killer Cells And Monocytes; Autoimmune Disorders; Vaccine
  • Immunogenic Composition Comprising Bacterial Or Viral Vector, Antigen And Toxins; Escherichia And Baculovirus; Vaccines
  • Immunostimulatory Nucleic Acids
  • Superior Molecular Vaccine Linking The Translocation Domain Of A Bacterial Toxin To An Antigen
  • Prophylactic And Therapeutic Immunization Against Protozoan Infection And Disease
  • Administering An Adenovirus Expression Vector, Expressing A Protein On Cancer Cells For Treating Ovarian Cancer, Cervical Cancer, Stomach Cancer And Lung Cancer
  • Malaria Vaccine And Methods Thereof Based Upon Novel Antigenic Domain Of Plasmodium Falciparum
  • Vagus Nerve Stimulation Responsive To A Tachycardia Precursor
  • Expression Vectors Encoding Epitopes Of Target-Associated Antigens And Methods For Their Design
  • Treatment And Prevention Of Neurodegenerative Diseases Using Gene Therapy
  • Pharmaceutical Compositions Comprising Purified Intact Bacterial Minicells
  • Synergistic Mixtures; Hepatitis Virus
  • Method Of Intranasal Gene Transfer For Protection Against Respiratory Infection
  • Treatment Of Immune Disease By Mucosal Delivery Of Antigens Using Genetically Modified Lactococcus
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Polynucleotide Composition, Method Of Preparation, And Use Thereof
  • Molecular Clones With Mutated Hiv Gag/Pol, Siv Gag And Siv Env Genes
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Dna And Methods Of Using The Same
  • Expression Vectors Encoding Epitopes Of Target-Associated Antigens And Methods For Their Design
  • For Generating An Immune Response In A Subject; Synthetic Expression Cassettes Generated From These And Other Hiv Sequences; Vaccines; Immunogenic Hiv Gag Polypeptide
  • Microorganisms For Therapy
  • Comprises Therapeutic Polypeptide For Prevention And Treatment Of Mycobacterial Infections, Cancers And Immunological Disorders Gene And Immunotherapy
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Anti-Cancer Dna Vaccine Employing Plasmids Encoding Signal Sequence, Mutant Oncoprotein Antigen, And Heat Shock Protein
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Dna And Methods Of Using The Same
  • Molecular Clones With Mutated Hiv Gag/Pol, Siv Gag And Siv Env Genes
  • Immunogens Comprising Plasmid Codes For Open Reading Frames Porcine Circovirus(Pcv) And Adjuvants Comprising Cationic Lipids; Immunology
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Immunostimulatory Nucleic Acid Molecules
  • Contacting The Tumor With A Cytokine, Provided That Said Cytokine Is Not Interleukin-7 Or Tumor Necrosis Factor- Alpha, Or Administering At A Site Other Than The Tumor A Cytokine And A Tumor Antigen.
  • Measles Vaccine Vectors And Methods Of Use
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Developing Genetic Vaccines To Prevent Trypanosoma Infections; Antiprotozoa Agents; Parasiticides
  • Immobilized Vaccine; Gene Therapy
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Baculovirus Expressing The Exogenous Nucleotide Sequence Porcine Circovirus-B (Pcvb) Open Reading Frame 2; Transformed Host Cells For Expressing Immunogenic Protein For Protecting Pigs Including Pregnant Pigs
  • Nucleotide Sequences Coding Polypeptide For Use In The Treatment And Prevention Of Immunological Defects And Mycobacterial Infections; Bactericides
  • A Recombinant Lister Vaccinia Virus, Comprising A Modified Thymidine Kinase Gene, A Modified Hemagglutinin Gene, And A Modified F3gene Or Locus, Each Gene Or Locus Is Denactivated; The Virus Comprises Heterologous Nucleic Acid Encoding A Gene; Antitumor,Carcinogenic, -Proliferative Agents; Nontoxic
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Nucleic Acid Compositions For Stimulating Immune Responses
  • Using Transition Metal Compound Promoter
  • For Inhibiting Neoplastic Cell Growth In A Human Or Mouse
  • Nucleic Acid Compositions For Stimulating Immune Responses
  • Expression Vectors Encoding Epitopes Of Target-Associated Antigens And Methods For Their Design
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Use Of Cpg Oligodeoxynucleotides To Induce Angiogenesis
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Microorganisms For Therapy
  • Allogeneic Cancer Cell-Based Immunotherapy
  • Polynucleotides Encoding Antigenic Hiv Type B Polypeptides, Polypeptides, And Uses Thereof
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Induction Of Mucosal Tolerance To Antigens
  • Vaccines Comprising An Immunostimulatory Peptide And An Immunostimulatory Oligodeoxynucleic Acid Molecule
  • Administering To A Mammal A B Lymphocyte Chemoattractant (Blc) Or A Polynucleotide Encoding A Blc, And A Plasmid Containing Single Promoter Derived From The Virus Linked To Sequence Encoding Viral Immonogen To Enhance Immune Response
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • For Generating An Immune Response In A Subject
  • Defective Expression Of The Gamma 34.5 Gene And The Ribonucleotide Reductase Gene
  • Vaccine
  • Therapeutic Compounds And Methods
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Include Recombinant Expression Constructs Containing Nucleic Acids Encoding Target Cell Surface Receptor Antigen And One Or More Immune Response Altering Molecules, Or The Expressed Products Themselves
  • Microorganisms For Therapy
  • Pcv2b Divergent Vaccine Composition And Methods Of Use
  • Vectors And Methods For Immunization Or Therapeutic Protocols
  • Incubating Monocytes In Nutrient Broth Comprising Interleukins, Cytokine And Modified Nucleotide Sequences; Propagate Cells; Recover Antigen-Presenting Dendritic Cell, Contact With T-Lymphocyte
  • Microorganisms For Therapy
  • Nucleotide Vector Vaccine For Immunization Against Hepatitis
  • Treatment Of Immune Disease By Mucosal Delivery Of Antigens Using Genetically Modified Lactococcus
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Induction Of Mucosal Tolerance To Antigens
  • Methods And Products For Inducing Mucosal Immunity
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Multicomponent Vaccine; Immunogenic Polypeptide That Contains A Membrane Translocating Sequence, To Facilitate Introduction Of The Polypeptide Into The Mammalian Cell And Subsequent Stimulation Of The Cell-Mediated Immune Response; Chagas' Disease
  • Microorganisms For Therapy
  • Rna Interference That Blocks Expression Of Pro-Apoptotic Proteins Potentiates Immunity Induced By Dna And Transfected Dendritic Cell Vaccines
  • Administering At Or Around The Solid Tumor An Expressible Nucleic Acid Encoding Interleukin-3, And Providing A Tumor Antigen, Then Treating The Tumor With Radiotherapy
  • Method To Enhance An Immune Response Of Nucleic Acid Vaccination
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf03402065

    DOI

    http://dx.doi.org/10.1007/bf03402065

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1074485462

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/10390545


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Chemical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0304", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medicinal and Biomolecular Chemistry", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Cutaneous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Intranasal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Oral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibody Formation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hepatitis B Surface Antigens", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hepatitis B Vaccines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunity, Cellular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intramuscular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intravenous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Macaca mulatta", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, Inbred BALB C", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Predictive Value of Tests", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "T-Lymphocytes, Cytotoxic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vaccines, DNA", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada", 
              "id": "http://www.grid.ac/institutes/grid.28046.38", 
              "name": [
                "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada", 
                "Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McCluskie", 
            "givenName": "Michael J.", 
            "id": "sg:person.01337224357.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337224357.57"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada", 
              "id": "http://www.grid.ac/institutes/grid.412687.e", 
              "name": [
                "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Millan", 
            "givenName": "Cynthia L. Brazolot", 
            "id": "sg:person.014200716477.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200716477.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA", 
              "id": "http://www.grid.ac/institutes/grid.415913.b", 
              "name": [
                "Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gramzinski", 
            "givenName": "Robert A.", 
            "id": "sg:person.01040316565.93", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040316565.93"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.168645.8", 
              "name": [
                "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Robinson", 
            "givenName": "Harriet L.", 
            "id": "sg:person.01350227236.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350227236.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.168645.8", 
              "name": [
                "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Santoro", 
            "givenName": "Joseph C.", 
            "id": "sg:person.01362275224.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362275224.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "PowderJect Vaccines, Madison, Wisconsin, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "PowderJect Vaccines, Madison, Wisconsin, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fuller", 
            "givenName": "James T.", 
            "id": "sg:person.015430354722.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015430354722.02"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "PowderJect Vaccines, Madison, Wisconsin, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "PowderJect Vaccines, Madison, Wisconsin, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Widera", 
            "givenName": "Georg", 
            "id": "sg:person.0741425665.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741425665.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "PowderJect Vaccines, Madison, Wisconsin, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "PowderJect Vaccines, Madison, Wisconsin, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Haynes", 
            "givenName": "Joel R.", 
            "id": "sg:person.01054341025.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054341025.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA", 
              "id": "http://www.grid.ac/institutes/grid.419681.3", 
              "name": [
                "Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Purcell", 
            "givenName": "Robert H.", 
            "id": "sg:person.01136664631.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136664631.42"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada", 
              "id": "http://www.grid.ac/institutes/grid.28046.38", 
              "name": [
                "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada", 
                "Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada", 
                "Department of Microbiology, Immunology and Biochemistry, Faculty of Medicine, University of Ottawa, Ottawa, Canada", 
                "School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Davis", 
            "givenName": "Heather L.", 
            "id": "sg:person.01342320235.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342320235.44"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/356152a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023052619", 
              "https://doi.org/10.1038/356152a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3300380", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007732450", 
              "https://doi.org/10.1038/sj.gt.3300380"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1096-1122", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052270183", 
              "https://doi.org/10.1038/nm1096-1122"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0297-167", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042860966", 
              "https://doi.org/10.1038/nbt0297-167"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/386410a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041946870", 
              "https://doi.org/10.1038/386410a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0498-397", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027672674", 
              "https://doi.org/10.1038/nm0498-397"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/374546a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034049921", 
              "https://doi.org/10.1038/374546a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0597-526", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030499063", 
              "https://doi.org/10.1038/nm0597-526"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03401734", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083229498", 
              "https://doi.org/10.1007/bf03401734"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1999-05-01", 
        "datePublishedReg": "1999-05-01", 
        "description": "BackgroundIn spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.Materials and MethodsEight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six non-injected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.ResultsIn one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 \u00b5g) was compared to ID and IM (100 \u00b5g) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 \u00b5g at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 \u00b5g by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.ConclusionsRoute of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf03402065", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1113628", 
            "issn": [
              "1076-1551", 
              "1528-3658"
            ], 
            "name": "Molecular Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "5"
          }
        ], 
        "keywords": [
          "non-human primates", 
          "immune response", 
          "gene gun", 
          "significant titers", 
          "mixed IgG1/IgG2a", 
          "hepatitis B surface antigen", 
          "BALB/c mice", 
          "anti-HBs values", 
          "anti-HBs titers", 
          "T lymphocyte activity", 
          "IgG1/IgG2a", 
          "influences immune responses", 
          "DNA-based immunization", 
          "B surface antigen", 
          "plasmid DNA vaccine", 
          "HBsAg-specific antibodies", 
          "plasma of mice", 
          "non-injected routes", 
          "method of delivery", 
          "IgG2a responses", 
          "lymphocyte activity", 
          "immunization schedule", 
          "single immunization", 
          "IM delivery", 
          "DNA vaccine", 
          "c mice", 
          "IM injection", 
          "optimal dose", 
          "surface antigen", 
          "IgG1 antibodies", 
          "low titers", 
          "high titers", 
          "rhesus monkeys", 
          "BackgroundIn spite", 
          "mice", 
          "immunization", 
          "different doses", 
          "titers", 
          "Additional studies", 
          "One study", 
          "weeks", 
          "monkeys", 
          "high levels", 
          "antibodies", 
          "HBsAg", 
          "injection", 
          "longer intervals", 
          "serum", 
          "HBs", 
          "primates", 
          "delivery", 
          "second study", 
          "response", 
          "IM", 
          "humans", 
          "IgG2a", 
          "vaccine", 
          "IgG1", 
          "antigen", 
          "levels", 
          "study", 
          "CTL", 
          "doses", 
          "administration", 
          "dose", 
          "MethodsEight", 
          "different routes", 
          "skin", 
          "second experiment", 
          "plasmid DNA", 
          "boost", 
          "first experiment", 
          "time", 
          "interval", 
          "later times", 
          "schedule", 
          "plasma", 
          "activity", 
          "cases", 
          "ID", 
          "number", 
          "route", 
          "results", 
          "plasmid", 
          "large number", 
          "IPER", 
          "DNA", 
          "spite", 
          "ability", 
          "SL", 
          "same time", 
          "values", 
          "number of routes", 
          "method", 
          "materials", 
          "vector", 
          "experiments", 
          "nature", 
          "species", 
          "strength", 
          "VW", 
          "gun", 
          "hierarchy"
        ], 
        "name": "Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates", 
        "pagination": "287-300", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1074485462"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf03402065"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "10390545"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf03402065", 
          "https://app.dimensions.ai/details/publication/pub.1074485462"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:23", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_337.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf03402065"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'


     

    This table displays all metadata directly associated to this object as RDF triples.

    366 TRIPLES      21 PREDICATES      158 URIs      139 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf03402065 schema:about N07c0137160ff47e99e75eac8778d9078
    2 N11ec9df4e6cc43f0b240282b0ca740be
    3 N1c3f9128d4c24e8f83ee549c51b65911
    4 N2fcbbe975e294653928fdfb4bb6744dc
    5 N30eae82780114cdb89b6cd178f6724fb
    6 N3f68a806e2e14fa087c016dfc39b2e40
    7 N52b951721f9a4aadb26084a3f4caad07
    8 N594363a478a94957b94029009fd7038a
    9 N5c644ea5589b4a619f6df4604ee2dd56
    10 N5f69c1cc7e0c4348b1ec2029390079b2
    11 N66500085238f44de9668a1263d147c7f
    12 N76d2cb59a4854447b524b3b440efa1ff
    13 N8e0f6f1e35f64e8bacda4cfafa708956
    14 N92d55a25a24348f480b64f6d00faccd0
    15 N998d9caf44da4f2da3343ca22c99aa39
    16 N9a279dde37184137979a73d8fec90c15
    17 Ndf02449908244342b8a49ce87f4deebe
    18 Ne61b4ee7e34e450680643bd489ec4aa7
    19 Ne65e26e402a24e5bbd4870af15b5882d
    20 anzsrc-for:03
    21 anzsrc-for:0304
    22 anzsrc-for:06
    23 anzsrc-for:0601
    24 schema:author Nd61747c2a74c4ad98e3fb92aefe75e2f
    25 schema:citation sg:pub.10.1007/bf03401734
    26 sg:pub.10.1038/356152a0
    27 sg:pub.10.1038/374546a0
    28 sg:pub.10.1038/386410a0
    29 sg:pub.10.1038/nbt0297-167
    30 sg:pub.10.1038/nm0498-397
    31 sg:pub.10.1038/nm0597-526
    32 sg:pub.10.1038/nm1096-1122
    33 sg:pub.10.1038/sj.gt.3300380
    34 schema:datePublished 1999-05-01
    35 schema:datePublishedReg 1999-05-01
    36 schema:description BackgroundIn spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.Materials and MethodsEight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six non-injected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.ResultsIn one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 µg) was compared to ID and IM (100 µg) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 µg at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 µg by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.ConclusionsRoute of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required.
    37 schema:genre article
    38 schema:isAccessibleForFree true
    39 schema:isPartOf N1fa98ea2b41d49689aec9656da624c45
    40 Nc9862fb6eba64b1f82af48ba893f77ec
    41 sg:journal.1113628
    42 schema:keywords Additional studies
    43 B surface antigen
    44 BALB/c mice
    45 BackgroundIn spite
    46 CTL
    47 DNA
    48 DNA vaccine
    49 DNA-based immunization
    50 HBs
    51 HBsAg
    52 HBsAg-specific antibodies
    53 ID
    54 IM
    55 IM delivery
    56 IM injection
    57 IPER
    58 IgG1
    59 IgG1 antibodies
    60 IgG1/IgG2a
    61 IgG2a
    62 IgG2a responses
    63 MethodsEight
    64 One study
    65 SL
    66 T lymphocyte activity
    67 VW
    68 ability
    69 activity
    70 administration
    71 anti-HBs titers
    72 anti-HBs values
    73 antibodies
    74 antigen
    75 boost
    76 c mice
    77 cases
    78 delivery
    79 different doses
    80 different routes
    81 dose
    82 doses
    83 experiments
    84 first experiment
    85 gene gun
    86 gun
    87 hepatitis B surface antigen
    88 hierarchy
    89 high levels
    90 high titers
    91 humans
    92 immune response
    93 immunization
    94 immunization schedule
    95 influences immune responses
    96 injection
    97 interval
    98 large number
    99 later times
    100 levels
    101 longer intervals
    102 low titers
    103 lymphocyte activity
    104 materials
    105 method
    106 method of delivery
    107 mice
    108 mixed IgG1/IgG2a
    109 monkeys
    110 nature
    111 non-human primates
    112 non-injected routes
    113 number
    114 number of routes
    115 optimal dose
    116 plasma
    117 plasma of mice
    118 plasmid
    119 plasmid DNA
    120 plasmid DNA vaccine
    121 primates
    122 response
    123 results
    124 rhesus monkeys
    125 route
    126 same time
    127 schedule
    128 second experiment
    129 second study
    130 serum
    131 significant titers
    132 single immunization
    133 skin
    134 species
    135 spite
    136 strength
    137 study
    138 surface antigen
    139 time
    140 titers
    141 vaccine
    142 values
    143 vector
    144 weeks
    145 schema:name Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates
    146 schema:pagination 287-300
    147 schema:productId N36ff6dec3cfd4c09ab50779312438f6b
    148 Na7dd3524f65a4c8d8546759b7ea663e1
    149 Nc4341b29a8d54daf97352f5756072ece
    150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074485462
    151 https://doi.org/10.1007/bf03402065
    152 schema:sdDatePublished 2022-12-01T06:23
    153 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    154 schema:sdPublisher N83a3d92c7f9b4a6886130ed4334fcf28
    155 schema:url https://doi.org/10.1007/bf03402065
    156 sgo:license sg:explorer/license/
    157 sgo:sdDataset articles
    158 rdf:type schema:ScholarlyArticle
    159 N07c0137160ff47e99e75eac8778d9078 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Administration, Intranasal
    161 rdf:type schema:DefinedTerm
    162 N11ec9df4e6cc43f0b240282b0ca740be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Injections, Intravenous
    164 rdf:type schema:DefinedTerm
    165 N1c3f9128d4c24e8f83ee549c51b65911 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Administration, Oral
    167 rdf:type schema:DefinedTerm
    168 N1e09312f93c5401c851bab73778689cc rdf:first sg:person.01342320235.44
    169 rdf:rest rdf:nil
    170 N1fa98ea2b41d49689aec9656da624c45 schema:volumeNumber 5
    171 rdf:type schema:PublicationVolume
    172 N2fcbbe975e294653928fdfb4bb6744dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Male
    174 rdf:type schema:DefinedTerm
    175 N30eae82780114cdb89b6cd178f6724fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Mice
    177 rdf:type schema:DefinedTerm
    178 N36ff6dec3cfd4c09ab50779312438f6b schema:name pubmed_id
    179 schema:value 10390545
    180 rdf:type schema:PropertyValue
    181 N3f68a806e2e14fa087c016dfc39b2e40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Predictive Value of Tests
    183 rdf:type schema:DefinedTerm
    184 N420f7958a6034bc1a414c7ce44de844f rdf:first sg:person.0741425665.18
    185 rdf:rest N59bb3234fbcc4a65b844793a25affad5
    186 N45af4c6e4423487ebd626ab68817a120 rdf:first sg:person.01136664631.42
    187 rdf:rest N1e09312f93c5401c851bab73778689cc
    188 N52b951721f9a4aadb26084a3f4caad07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Hepatitis B Surface Antigens
    190 rdf:type schema:DefinedTerm
    191 N57a776d66c9245b5a0a36c3dd4bbb2eb rdf:first sg:person.015430354722.02
    192 rdf:rest N420f7958a6034bc1a414c7ce44de844f
    193 N594363a478a94957b94029009fd7038a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Time Factors
    195 rdf:type schema:DefinedTerm
    196 N59bb3234fbcc4a65b844793a25affad5 rdf:first sg:person.01054341025.16
    197 rdf:rest N45af4c6e4423487ebd626ab68817a120
    198 N5c644ea5589b4a619f6df4604ee2dd56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Female
    200 rdf:type schema:DefinedTerm
    201 N5f69c1cc7e0c4348b1ec2029390079b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    202 schema:name Immunity, Cellular
    203 rdf:type schema:DefinedTerm
    204 N66500085238f44de9668a1263d147c7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    205 schema:name T-Lymphocytes, Cytotoxic
    206 rdf:type schema:DefinedTerm
    207 N6edef7f342c744e49a60798d7cd85840 rdf:first sg:person.01362275224.11
    208 rdf:rest N57a776d66c9245b5a0a36c3dd4bbb2eb
    209 N6f57ecaa9b0e4c1396dbd472f35997c0 rdf:first sg:person.01040316565.93
    210 rdf:rest Neddfe56c89c54c17a3939b672dfdb613
    211 N76d2cb59a4854447b524b3b440efa1ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    212 schema:name Vaccines, DNA
    213 rdf:type schema:DefinedTerm
    214 N83a3d92c7f9b4a6886130ed4334fcf28 schema:name Springer Nature - SN SciGraph project
    215 rdf:type schema:Organization
    216 N8e0f6f1e35f64e8bacda4cfafa708956 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    217 schema:name Mice, Inbred BALB C
    218 rdf:type schema:DefinedTerm
    219 N92d55a25a24348f480b64f6d00faccd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    220 schema:name Administration, Cutaneous
    221 rdf:type schema:DefinedTerm
    222 N998d9caf44da4f2da3343ca22c99aa39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Antibody Formation
    224 rdf:type schema:DefinedTerm
    225 N9a279dde37184137979a73d8fec90c15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    226 schema:name Macaca mulatta
    227 rdf:type schema:DefinedTerm
    228 N9f3f8c43d727467e807188a09d8be35b rdf:first sg:person.014200716477.00
    229 rdf:rest N6f57ecaa9b0e4c1396dbd472f35997c0
    230 Na7dd3524f65a4c8d8546759b7ea663e1 schema:name dimensions_id
    231 schema:value pub.1074485462
    232 rdf:type schema:PropertyValue
    233 Nc4341b29a8d54daf97352f5756072ece schema:name doi
    234 schema:value 10.1007/bf03402065
    235 rdf:type schema:PropertyValue
    236 Nc9862fb6eba64b1f82af48ba893f77ec schema:issueNumber 5
    237 rdf:type schema:PublicationIssue
    238 Nd61747c2a74c4ad98e3fb92aefe75e2f rdf:first sg:person.01337224357.57
    239 rdf:rest N9f3f8c43d727467e807188a09d8be35b
    240 Ndf02449908244342b8a49ce87f4deebe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    241 schema:name Injections, Intramuscular
    242 rdf:type schema:DefinedTerm
    243 Ne61b4ee7e34e450680643bd489ec4aa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    244 schema:name Animals
    245 rdf:type schema:DefinedTerm
    246 Ne65e26e402a24e5bbd4870af15b5882d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    247 schema:name Hepatitis B Vaccines
    248 rdf:type schema:DefinedTerm
    249 Neddfe56c89c54c17a3939b672dfdb613 rdf:first sg:person.01350227236.96
    250 rdf:rest N6edef7f342c744e49a60798d7cd85840
    251 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    252 schema:name Chemical Sciences
    253 rdf:type schema:DefinedTerm
    254 anzsrc-for:0304 schema:inDefinedTermSet anzsrc-for:
    255 schema:name Medicinal and Biomolecular Chemistry
    256 rdf:type schema:DefinedTerm
    257 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    258 schema:name Biological Sciences
    259 rdf:type schema:DefinedTerm
    260 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    261 schema:name Biochemistry and Cell Biology
    262 rdf:type schema:DefinedTerm
    263 sg:journal.1113628 schema:issn 1076-1551
    264 1528-3658
    265 schema:name Molecular Medicine
    266 schema:publisher Springer Nature
    267 rdf:type schema:Periodical
    268 sg:person.01040316565.93 schema:affiliation grid-institutes:grid.415913.b
    269 schema:familyName Gramzinski
    270 schema:givenName Robert A.
    271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040316565.93
    272 rdf:type schema:Person
    273 sg:person.01054341025.16 schema:affiliation grid-institutes:None
    274 schema:familyName Haynes
    275 schema:givenName Joel R.
    276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054341025.16
    277 rdf:type schema:Person
    278 sg:person.01136664631.42 schema:affiliation grid-institutes:grid.419681.3
    279 schema:familyName Purcell
    280 schema:givenName Robert H.
    281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136664631.42
    282 rdf:type schema:Person
    283 sg:person.01337224357.57 schema:affiliation grid-institutes:grid.28046.38
    284 schema:familyName McCluskie
    285 schema:givenName Michael J.
    286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337224357.57
    287 rdf:type schema:Person
    288 sg:person.01342320235.44 schema:affiliation grid-institutes:grid.28046.38
    289 schema:familyName Davis
    290 schema:givenName Heather L.
    291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342320235.44
    292 rdf:type schema:Person
    293 sg:person.01350227236.96 schema:affiliation grid-institutes:grid.168645.8
    294 schema:familyName Robinson
    295 schema:givenName Harriet L.
    296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350227236.96
    297 rdf:type schema:Person
    298 sg:person.01362275224.11 schema:affiliation grid-institutes:grid.168645.8
    299 schema:familyName Santoro
    300 schema:givenName Joseph C.
    301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362275224.11
    302 rdf:type schema:Person
    303 sg:person.014200716477.00 schema:affiliation grid-institutes:grid.412687.e
    304 schema:familyName Millan
    305 schema:givenName Cynthia L. Brazolot
    306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200716477.00
    307 rdf:type schema:Person
    308 sg:person.015430354722.02 schema:affiliation grid-institutes:None
    309 schema:familyName Fuller
    310 schema:givenName James T.
    311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015430354722.02
    312 rdf:type schema:Person
    313 sg:person.0741425665.18 schema:affiliation grid-institutes:None
    314 schema:familyName Widera
    315 schema:givenName Georg
    316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741425665.18
    317 rdf:type schema:Person
    318 sg:pub.10.1007/bf03401734 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083229498
    319 https://doi.org/10.1007/bf03401734
    320 rdf:type schema:CreativeWork
    321 sg:pub.10.1038/356152a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023052619
    322 https://doi.org/10.1038/356152a0
    323 rdf:type schema:CreativeWork
    324 sg:pub.10.1038/374546a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034049921
    325 https://doi.org/10.1038/374546a0
    326 rdf:type schema:CreativeWork
    327 sg:pub.10.1038/386410a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041946870
    328 https://doi.org/10.1038/386410a0
    329 rdf:type schema:CreativeWork
    330 sg:pub.10.1038/nbt0297-167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042860966
    331 https://doi.org/10.1038/nbt0297-167
    332 rdf:type schema:CreativeWork
    333 sg:pub.10.1038/nm0498-397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027672674
    334 https://doi.org/10.1038/nm0498-397
    335 rdf:type schema:CreativeWork
    336 sg:pub.10.1038/nm0597-526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030499063
    337 https://doi.org/10.1038/nm0597-526
    338 rdf:type schema:CreativeWork
    339 sg:pub.10.1038/nm1096-1122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052270183
    340 https://doi.org/10.1038/nm1096-1122
    341 rdf:type schema:CreativeWork
    342 sg:pub.10.1038/sj.gt.3300380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007732450
    343 https://doi.org/10.1038/sj.gt.3300380
    344 rdf:type schema:CreativeWork
    345 grid-institutes:None schema:alternateName PowderJect Vaccines, Madison, Wisconsin, USA
    346 schema:name PowderJect Vaccines, Madison, Wisconsin, USA
    347 rdf:type schema:Organization
    348 grid-institutes:grid.168645.8 schema:alternateName Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    349 schema:name Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    350 rdf:type schema:Organization
    351 grid-institutes:grid.28046.38 schema:alternateName Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    352 School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    353 schema:name Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    354 Department of Microbiology, Immunology and Biochemistry, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    355 Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada
    356 School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    357 rdf:type schema:Organization
    358 grid-institutes:grid.412687.e schema:alternateName Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada
    359 schema:name Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada
    360 rdf:type schema:Organization
    361 grid-institutes:grid.415913.b schema:alternateName Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA
    362 schema:name Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA
    363 rdf:type schema:Organization
    364 grid-institutes:grid.419681.3 schema:alternateName Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    365 schema:name Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    366 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...